GALWAY, Ireland — December 6, 2021 — Aran Biomedical has expanded its weaving capabilities to include the condensing of high-density woven fabric. This technology breakthrough combines Aran’s existing compression techniques with dense woven fabric, allowing for the same material characteristics despite the thickness being dramatically reduced by approximately 50 percent.
Condensed fabrics utilize a proprietary process developed at Aran Biomedical, ensuring textile based finished devices and components are available at their lowest thicknesses. Our process typically leads to minimum reduction of 50 percent, but this can be as high as 70 percent depending on the configuration. An additional benefit of fabric condensing is reduced permeability as yarns flatten and spread out, without affecting the mechanical characteristics of the fabric. Woven fabric that has been condensed from 70 microns to 35 microns thick, shows a reduced permeability range between 300-350 ml/cm2/min.
These woven textiles are predominantly used in the structural heart and vascular spaces, more specifically for the development of heart valve skirts, occlusion devices, synthetic grafts, vascular stents, and endovascular devices. Aran Biomedical believes this new technology expansion will lead to further profile reductions in established devices and potentially lead to the development of more minimally invasive therapies in the space. This technology expansion compliments Aran Biomedical’s established platform technology, ValvTEX. This proprietary technique creates suture free textile covering for mitral, aortic, and tricuspid heart valves.
This Technology Expansion Allows For:
- Enhanced Crimpability;
- Wide Range of Implantable Input Materials; and
- Tailored Permeability.
Our proprietary condensing technology is available across our full textile development portfolio i.e. knitting, weaving and braiding, and can be applied to an extensive range of input biomaterials including resorbable polymers.
Posted December 6, 2021
Source: Aran Biomedical